BETA

9 Amendments of Raphaël GLUCKSMANN related to 2020/2071(INI)

Amendment 3 #
Draft opinion
Paragraph 1
1. Notes that the COVID-19 pandemic has revealed in the starkest possible terms the vital role played by functioning global supply chains for medical products, and in particular for medicines; emphasises that an open, rules-based trading system is fundamental to ensuring the global availability of medicines;
2020/05/18
Committee: INTA
Amendment 19 #
Draft opinion
Paragraph 2
2. RecognisDeplores that the EU depends on a narrow set of countries for a large proportion of its imports of active pharmaceutical ingredients and chemical raw materials; stresses that this over- reliance can poses a risk in times of crises, when limitations in production capacity, excess demand or protectionist measures threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long- term strategy focused on ensuring the EU’s open strategic autonomy in health, strengthening the European production of essential medicines;
2020/05/18
Committee: INTA
Amendment 27 #
3. Emphasises that the EU is a leading global exporter of pharmaceutical products; notes that the protection and enforcement of IP rights in free trade agreements (FTAs) and at the WTO is crucial to the development of new medicines and treatments; underlines that the flexibilities provided in the TRIPS agreement can be used to address potential supply shortages in exceptional circumstanchowever that the TRIPS agreement should be reviewed to ensure that it meets developing countries’ access to essential medicines;
2020/05/18
Committee: INTA
Amendment 34 #
Draft opinion
Paragraph 3 a (new)
3 a. Acknowledges that the EU’s recent trade agreements includes clear rules on commercial aspects of intellectual property rights, which generally acknowledge the issuing of compulsory licences in line with the TRIPS agreement; however, provisions such as data exclusivity enhanced patent protection and the protection of trade secrets, could possibly make it more difficult for many countries to invoke such clauses to their fullest effect; calls upon the Commission to give the Parliament an assessment of what role the EU free trade agreements and TRIPS can provide in this situation, including whether the Commission is considering guidelines in which voluntary licensing could be encouraged over immediate compulsory licensing;
2020/05/18
Committee: INTA
Amendment 39 #
Draft opinion
Paragraph 4
4. Emphasises that a broad network of FTAs together withWelcomes the Commissioner for Internal Market’s statements on the reshoring of strategic supply chains; notes that a functioning multilateral trading system constitute the best way of guaranteeing that multiple sources of manufacturing for essential medicines are available and regulatory standards converge globallycould serve as a complement to the European production;
2020/05/18
Committee: INTA
Amendment 51 #
Draft opinion
Paragraph 5 a (new)
5 a. Notes that the whole world is fighting the COVID-19 pandemic, as no available medication that can fight the disease has been found yet; calls upon the Commission to coordinate with the WTO and the WHO that all countries, and in particular the developing countries, have equal access in case of any breakthrough drugs; encourages all member states to make efforts to establish a pool of patent rights for COVID-19 technologies at the WHO;
2020/05/18
Committee: INTA
Amendment 59 #
Draft opinion
Paragraph 6
6. Underlines that a complete repatriation of all medical supply chains is not possible in a global economy; urges the Commission and the Member States to work with the EU’s partners, the WHO and WTO, on establishing an international framework that can prevent the breakdown of supply chains and limit resort to protectionist measures during health crises.
2020/05/18
Committee: INTA
Amendment 64 #
Draft opinion
Paragraph 6 a (new)
6 a. Calls upon the Commission and the Member States to make sure that there is a constant and reliable supply of medical products; stresses that the development of medical products has to be in line with the international standards of human rights, in compliance with the Paris agreement, and that labour rights are in compliance with the ILO conventions; calls on the Commission that to maintain a level playing field in the internal market a common European approach for binding supply chain law is urgently needed;
2020/05/18
Committee: INTA
Amendment 67 #
Draft opinion
Paragraph 6 b (new)
6 b. Emphasises the importance of European safety standards for medical products; urges the Commission to check medical products entering our internal market that they uphold to the European safety standards; calls upon the Commission to ensure that consumer protection is prioritised in the WTO negotiations on e-commerce in negotiation;
2020/05/18
Committee: INTA